Global Genome Editing Market Size, Share, Trends & Growth Analysis Report 2026-2034

Description

The Genome Editing Market size is expected to reach USD 28.96 Billion in 2034 from USD 8.81 Billion (2025) growing at a CAGR of 14.14% during 2026-2034.

The Global Genome Editing Market is witnessing significant growth driven by advancements in genetic engineering technologies. Tools such as CRISPR-based systems are enabling precise modification of DNA sequences for research and therapeutic purposes. Increasing focus on gene therapy, agricultural biotechnology, and disease modeling is supporting market expansion. Rising investments in biotechnology research are further accelerating innovation.

Major growth drivers include growing demand for personalized medicine and treatment of genetic disorders. Pharmaceutical companies are exploring genome editing for targeted therapies. Government funding and supportive regulatory frameworks in developed regions are strengthening research activities. Additionally, expanding applications in crop improvement and livestock breeding are contributing to market growth.

Future prospects remain strong as technological advancements improve editing accuracy and safety. Emerging markets investing in biotechnology infrastructure will present new opportunities. Ethical considerations and regulatory developments will shape market dynamics. As genetic research continues to evolve, the Global Genome Editing Market is projected to experience sustained expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

CRISPR/Cas9
TALENs/MegaTALs
Prime Editing
Base Editing
Cpf1 (CRISPR from Prevotella and Francisella 1)
CasX and CasY
ZFN
Meganucleases
Oligonucleotide-Directed Mutagenesis (ODM)
Synthetic Gene Editors
Transcription Activator-Like Effector Base Editors (TALE-BE)
Other

By Delivery Method

Ex-vivo
In-vivo

By Application

Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others)
Clinical Applications (Diagnostics, Therapy Development)
Others

By End-use

Biotechnology and Pharmaceutical Companies
Academic and Government Research Institutes
Contract Research Organizations

By Mode

Contract
In-House

COMPANIES PROFILED

Merck KGaA, Cibus Inc, Recombinetics, Sangamo Therapeutics, Editas Medicine, Precision Biosciences, CRISPR Therapeutics, Intellia Therapeutics Inc, Caribou Biosciences Inc, Cellectis SA, AstraZeneca, Takara Bio Inc, Horizon Discovery Ltd Revvity Inn Inc
We can customise the report as per your requirements.

Product Code: VMR112112859

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL GENOME EDITING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Technology
4.2. CRISPR/Cas9 Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. TALENs/MegaTALs Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Prime Editing Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Base Editing Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.6. Cpf1 (CRISPR from Prevotella and Francisella 1) Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.7. CasX and CasY Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.8. ZFN Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.9. Meganucleases Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.10. Oligonucleotide-Directed Mutagenesis (ODM) Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.11. Synthetic Gene Editors Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.12. Transcription Activator-Like Effector Base Editors (TALE-BE) Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.13. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GENOME EDITING MARKET: BY DELIVERY METHOD 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Delivery Method
5.2. Ex-vivo Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. In-vivo Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GENOME EDITING MARKET: BY APPLICATION 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast Application
6.2. Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Clinical Applications (Diagnostics, Therapy Development) Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GENOME EDITING MARKET: BY END-USE 2022-2034 (USD MN)

7.1. Market Analysis, Insights and Forecast End-use
7.2. Biotechnology and Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.3. Academic and Government Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.4. Contract Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GENOME EDITING MARKET: BY MODE 2022-2034 (USD MN)

8.1. Market Analysis, Insights and Forecast Mode
8.2. Contract Estimates and Forecasts By Regions 2022-2034 (USD MN)
8.3. In-House Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL GENOME EDITING MARKET: BY REGION 2022-2034(USD MN)

9.1. Regional Outlook
9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.2.1 By Technology
- 9.2.2 By Delivery Method
- 9.2.3 By Application
- 9.2.4 By End-use
- 9.2.5 By Mode
- 9.2.6 United States
- 9.2.7 Canada
- 9.2.8 Mexico
9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.3.1 By Technology
- 9.3.2 By Delivery Method
- 9.3.3 By Application
- 9.3.4 By End-use
- 9.3.5 By Mode
- 9.3.6 United Kingdom
- 9.3.7 France
- 9.3.8 Germany
- 9.3.9 Italy
- 9.3.10 Russia
- 9.3.11 Rest Of Europe
9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.4.1 By Technology
- 9.4.2 By Delivery Method
- 9.4.3 By Application
- 9.4.4 By End-use
- 9.4.5 By Mode
- 9.4.6 India
- 9.4.7 Japan
- 9.4.8 South Korea
- 9.4.9 Australia
- 9.4.10 South East Asia
- 9.4.11 Rest Of Asia Pacific
9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.5.1 By Technology
- 9.5.2 By Delivery Method
- 9.5.3 By Application
- 9.5.4 By End-use
- 9.5.5 By Mode
- 9.5.6 Brazil
- 9.5.7 Argentina
- 9.5.8 Peru
- 9.5.9 Chile
- 9.5.10 South East Asia
- 9.5.11 Rest of Latin America
9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 9.6.1 By Technology
- 9.6.2 By Delivery Method
- 9.6.3 By Application
- 9.6.4 By End-use
- 9.6.5 By Mode
- 9.6.6 Saudi Arabia
- 9.6.7 UAE
- 9.6.8 Israel
- 9.6.9 South Africa
- 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

10.1. Recent Developments
10.2. Company Categorization
10.3. Supply Chain & Channel Partners (based on availability)
10.4. Market Share & Positioning Analysis (based on availability)
10.5. Vendor Landscape (based on availability)
10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL GENOME EDITING INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Company Profiles
- 11.2.1 Merck KGaA
- 11.2.2 Cibus Inc
- 11.2.3 Recombinetics
- 11.2.4 Sangamo Therapeutics
- 11.2.5 Editas Medicine
- 11.2.6 Precision Biosciences
- 11.2.7 CRISPR Therapeutics
- 11.2.8 Intellia Therapeutics Inc
- 11.2.9 Caribou Biosciences Inc
- 11.2.10 Cellectis S.A
- 11.2.11 AstraZeneca
- 11.2.12 Takara Bio Inc
- 11.2.13 Horizon Discovery Ltd. (Revvity Inn Inc.)